• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Idarucizumab for dabigatran overdose in a child.

作者信息

Shapiro Susan, Bhatnagar Neha, Khan Asif, Beavis James, Keeling David

机构信息

Oxford Haemophilia and Thrombosis Centre, Oxford University Hospitals NHS Foundation Trust, Oxford Comprehensive Biomedical Resource Centre*, Oxford, UK.

Department of Paediatric Haematology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

出版信息

Br J Haematol. 2018 Feb;180(3):457-459. doi: 10.1111/bjh.14371. Epub 2016 Oct 13.

DOI:10.1111/bjh.14371
PMID:27734469
Abstract
摘要

相似文献

1
Idarucizumab for dabigatran overdose in a child.依达赛珠单抗用于儿童达比加群过量
Br J Haematol. 2018 Feb;180(3):457-459. doi: 10.1111/bjh.14371. Epub 2016 Oct 13.
2
Idarucizumab for dabigatran overdose.依达赛珠单抗用于达比加群过量。
Clin Toxicol (Phila). 2016 Sep;54(8):644-6. doi: 10.1080/15563650.2016.1187737. Epub 2016 May 25.
3
Reversal of dabigatran by idarucizumab: when and how?依达鲁单抗逆转达比加群：何时及如何逆转？
Expert Rev Hematol. 2016 Jun;9(6):519-28. doi: 10.1080/17474086.2016.1184569.
4
Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.关注艾达司珠单抗及其逆转达比加群抗凝作用的潜力。
Drug Des Devel Ther. 2016 May 18;10:1683-9. doi: 10.2147/DDDT.S94167. eCollection 2016.
5
Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report.艾达司珠单抗用于急性手术前达比加群的逆转：基于病例报告的示意性方法
Basic Clin Pharmacol Toxicol. 2017 Apr;120(4):407-410. doi: 10.1111/bcpt.12696. Epub 2016 Dec 16.
6
Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.依达赛珠单抗用于逆转达比加群相关抗凝作用
Ann Pharmacother. 2016 Oct;50(10):847-54. doi: 10.1177/1060028016659504. Epub 2016 Jul 7.
7
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.依达赛珠单抗，一种达比加群的特异性逆转剂：作用机制、药代动力学和药效学以及1期受试者的安全性和有效性。
Am J Med. 2016 Nov;129(11S):S64-S72. doi: 10.1016/j.amjmed.2016.06.007. Epub 2016 Aug 26.
8
Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab-A Case Report.使用依达赛珠单抗逆转达比加群酯后急性缺血性卒中的全身溶栓治疗——病例报告
J Stroke Cerebrovasc Dis. 2017 Jul;26(7):e123-e125. doi: 10.1016/j.jstrokecerebrovasdis.2017.03.039. Epub 2017 May 4.
9
Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan.依达赛珠单抗逆转达比加群治疗患者抗凝作用的真实世界经验：来自台湾的11例报告
J Stroke Cerebrovasc Dis. 2018 Feb;27(2):e27-e33. doi: 10.1016/j.jstrokecerebrovasdis.2017.09.044. Epub 2017 Nov 6.
10
Idarucizumab: First Global Approval.依达鲁珠单抗：全球首次获批
Drugs. 2015 Dec;75(18):2155-61. doi: 10.1007/s40265-015-0508-5.

引用本文的文献

1
Dabigatran-reversal failure using standard dose of idarucizumab: a systematic review and meta-analysis of cases.使用标准剂量艾达赛珠单抗进行达比加群逆转失败：病例的系统评价和荟萃分析
Res Pract Thromb Haemost. 2023 Jun 8;7(5):100201. doi: 10.1016/j.rpth.2023.100201. eCollection 2023 Jul.
2
How I treat pediatric venous thromboembolism in the DOAC era.在新型口服抗凝药物时代，我如何治疗儿童静脉血栓栓塞症。
Blood. 2024 Feb 1;143(5):389-403. doi: 10.1182/blood.2022018966.
3
Practical Considerations for Use of Direct Oral Anticoagulants in Children.
儿童使用直接口服抗凝剂的实际考量
Front Pediatr. 2022 Apr 1;10:860369. doi: 10.3389/fped.2022.860369. eCollection 2022.
4
Direct Oral Anticoagulants: Novel Approach for the Treatment of Thrombosis in Pediatric Patients?直接口服抗凝剂：治疗儿科患者血栓形成的新方法？
Pediatr Cardiol. 2019 Oct;40(7):1431-1438. doi: 10.1007/s00246-019-02159-3. Epub 2019 Jul 20.
5
Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism.伊达比星单抗用于接受达比加群酯治疗静脉血栓栓塞症儿童的III期安全性试验的原理与设计
Res Pract Thromb Haemost. 2017 Nov 17;2(1):69-76. doi: 10.1002/rth2.12053. eCollection 2018 Jan.
6
The Use of Idarucizumab for Dabigatran Reversal in Clinical Practice: A Case Series.依达赛珠单抗在临床实践中用于达比加群逆转的病例系列研究
P T. 2017 Nov;42(11):699-703.
7
Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.艾达赛珠单抗（Praxbind）逆转直接凝血酶抑制剂达比加群作用的证据：RE-VERSE AD全队列分析后的综述
P T. 2017 Nov;42(11):692-698.